| Literature DB >> 34813734 |
Lichao Wang1, Binsheng Wang1, Nathan S Gasek1, Yueying Zhou2, Rachel L Cohn1, Dominique E Martin3, Wulin Zuo4, William F Flynn4, Chun Guo5, Evan R Jellison6, Taewan Kim3, Larissa G P Langhi Prata7, Allyson K Palmer7, Ming Li8, Christina L Inman7, Lauren S Barber5, Iman M A Al-Naggar5, Yanjiao Zhou9, Wenqiang Du10, George A Kuchel5, Alexander Meves8, Tamar Tchkonia7, James L Kirkland7, Paul Robson11, Ming Xu12.
Abstract
Insulin resistance is a pathological state often associated with obesity, representing a major risk factor for type 2 diabetes. Limited mechanism-based strategies exist to alleviate insulin resistance. Here, using single-cell transcriptomics, we identify a small, critically important, but previously unexamined cell population, p21Cip1 highly expressing (p21high) cells, which accumulate in adipose tissue with obesity. By leveraging a p21-Cre mouse model, we demonstrate that intermittent clearance of p21high cells can both prevent and alleviate insulin resistance in obese mice. Exclusive inactivation of the NF-κB pathway within p21high cells, without killing them, attenuates insulin resistance. Moreover, fat transplantation experiments establish that p21high cells within fat are sufficient to cause insulin resistance in vivo. Importantly, a senolytic cocktail, dasatinib plus quercetin, eliminates p21high cells in human fat ex vivo and mitigates insulin resistance following xenotransplantation into immuno-deficient mice. Our findings lay the foundation for pursuing the targeting of p21high cells as a new therapy to alleviate insulin resistance.Entities:
Keywords: Cellular senescence; NF-κB; diabetes; fat transplantation; senolytics; xenograft
Mesh:
Year: 2021 PMID: 34813734 PMCID: PMC8732323 DOI: 10.1016/j.cmet.2021.11.002
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287